Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Bradley Ertel

Physical Medicine & Rehabilitation Buffalo, NY Medical Doctor

NPI 1932360773 CMS profile 1311121

2950 Elmwood Ave, Buffalo, NY 14217

Open in the dashboard

General payments

$4,264

202 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bradley Ertel of Buffalo, NY is reported in the CMS Open Payments database as having received $4,264 across 202 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $544 31
2024 General $694 38
2023 General $1,530 62
2022 General $990 43
2021 General $377 19
2020 General $129 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bradley Ertel
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Bradley Ertel were reported at $544. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Bradley Ertel Physical Medicine & Rehabilitation median Middle half National median
2019 $0 $133 $45–$390 $163
2020 $129 $88 $29–$272 $114
2021 $377 $116 $33–$360 $132
2022 $990 $123 $40–$378 $149
2023 $1,530 $131 $43–$396 $160
2024 $694 $141 $45–$409 $164
2025 $544 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Smith+Nephew, Inc. $1,750 107 payments
  2. Organogenesis Inc. $750 36 payments
  3. Tactile Systems Technology Inc $545 17 payments
  4. Paratek Pharmaceuticals, Inc. $231 7 payments
  5. Acera Surgical, Inc. $226 2 payments
  6. KCI USA, Inc $143 2 payments
  7. Hartmann USA, Inc. $112 4 payments
  8. Allergan Inc. $63 4 payments
  9. Solventum Corporation $53 2 payments
  10. AbbVie, Inc. $49 3 payments
  11. Other $342 18 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $4,264 202 payments
Products named General payments · program years 2020–2025
  1. COLLAGENASE SANTYL $1,060 64 payments
  2. Flexitouch Plus $517 15 payments
  3. Puraply $380 15 payments
  4. Entre Plus $284 5 payments
  5. ALLEVYN LIFE L 15.4X15.4 CTN10 $258 17 payments
  6. ACTICOAT 4" X 4" $251 14 payments
  7. NUZYRA $231 7 payments
  8. Restrata Wound Matrix $226 2 payments
  9. DURAMAX S Silicone super absorbent dressing $222 13 payments
  10. entre $186 8 payments
  11. Other $2,172 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

606

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$71,843

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

36.1%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 160 $67,204
Doxycycline Hyclate Generic 165 $1,244
Linezolid Generic 26 $819
Ammonium Lactate Generic 21 $649
Clindamycin Hcl Generic 17 $432
Clobetasol Propionate Generic 28 $358
Levofloxacin Generic 54 $197
Nyamyc Nystatin Brand 20 $192
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 11 $176
Mupirocin Generic 23 $169

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$63,663

Medicare's payments for the services billed

Medicare patients

331

Average age 74

Services billed

1,287

160 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Chronic kidney disease 56%
Diabetes 55%
Ischemic heart disease 46%
Heart failure 41%
Atrial fibrillation 40%
Depression 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

202 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record